Patients with muscular dystrophies and their caregivers, including families and clinical teams, face significant challenges. These individuals often experience progressive difficulties in breathing and sleeping, along with decreased exercise tolerance due to cardiorespiratory insufficiency. This takes a substantial toll on them and their families. The purpose of this NOSI renewal is to enhance basic, translational, and clinical research in the cardiorespiratory and sleep complications associated with muscular dystrophies. The goals include elucidating phenotypes, optimizing metrics for early diagnosis, refining therapies such as gene therapy delivery to cardiac and respiratory muscles, and exploring mechanisms and treatment strategies for sleep-disordered breathing (SDB).

Muscular dystrophies are a heterogeneous group of congenital diseases, including Duchenne muscular dystrophy (DMD), facioscapulohumeral muscular dystrophy (FSHD), and myotonic dystrophy (DM), all leading to progressive

Click this link to continue reading the article on the source website.

The purpose of this Special Emphasis Notice (SEN) is to inform the research community of the Agency for Healthcare Research and Quality’s (AHRQ) strong and continued interest in receiving health services research grant applications for addressing Emergency Department (ED) boarding and hospital crowding. We seek system-wide innovations to reduce or eliminate crowding and boarding so patients receive timely, condition-appropriate care without adverse events from delayed, omitted, harmful, or distracted care. We also seek research that addresses challenges and proposes care solutions that comply with Emergency Medical Treatment and Labor Act (EMTALA) obligations, deliver effective and efficient system-wide Emergency Medical Services (EMS), and reduce diagnostic error, staff burnout, and turnover in ED and emergency care settings.

Approximately 140 million visits are made

Click this link to continue reading the article on the source website.

The National Institute of Allergy and Infectious Diseases (NIAID), one of 27 institutes of the National Institutes of Health, an agency within the Department of Health and Human Services (DHHS), conducts and supports research to understand, treat, and ultimately prevent the myriad infectious, immunologic, and allergic diseases that threaten millions of human lives. Through a variety of research grants and contracts, NIAID’s Division of Microbiology and Infectious Diseases (DMID) specifically supports extramural research to develop new medical countermeasures (MCMs) against potential agents of bioterrorism, drug-resistant pathogens, and emerging and re-emerging infectious diseases. This Broad Agency Announcement (BAA) is soliciting proposals to advance the research and development of promising candidate therapeutics, vaccines, and diagnostics for biodefense and emerging infectious diseases.

The Omnibus BAA is governed by Federal Acquisition Regulation

Click this link to continue reading the article on the source website.